Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Uric acid transport and disease
Alexander So, Bernard Thorens
Alexander So, Bernard Thorens
Published June 1, 2010
Citation Information: J Clin Invest. 2010;120(6):1791-1799. https://doi.org/10.1172/JCI42344.
View: Text | PDF
Science in Medicine Article has an altmetric score of 16

Uric acid transport and disease

  • Text
  • PDF
Abstract

Uric acid is the metabolic end product of purine metabolism in humans. It has antioxidant properties that may be protective but can also be pro-oxidant, depending on its chemical microenvironment. Hyperuricemia predisposes to disease through the formation of urate crystals that cause gout, but hyperuricemia, independent of crystal formation, has also been linked with hypertension, atherosclerosis, insulin resistance, and diabetes. We discuss here the biology of urate metabolism and its role in disease. We also cover the genetics of urate transport, including URAT1, and recent studies identifying SLC2A9, which encodes the glucose transporter family isoform Glut9, as a major determinant of plasma uric acid levels and of gout development.

Authors

Alexander So, Bernard Thorens

×

Figure 2

Antioxidant and pro-oxidant effect of uric acid.

Options: View larger image (or click on image) Download as PowerPoint
Antioxidant and pro-oxidant effect of uric acid.
Antioxidant activities....
Antioxidant activities. (A) Peroxynitrites (ONOO–) are produced from the reaction of nitric oxide (NO•) with superoxide (O2–•). Peroxynitrites can induce protein nitrosation and lipid and protein peroxidation and block tetrahydrobiopterin (HB4), a cofactor necessary for NOS activity. In the absence of HB4, NOS produces ROS. Uric acid (UA) can directly inactivate peroxynitrite by a reaction that generates uric acid radicals (UA•); these can be rapidly eliminated by plasma ascorbic acid. (B) Uric acid can also prevent Cu2+-induced oxidation of LDL, a reaction that may protect against atherosclerosis development. (C) By enhancing arginase activity, uric acid diverts l-arginine from NO production to urea production. Uric acid can also directly react with NO to generate nitrosated uric acid, and the nitroso group can then be transferred to glutathione (GSH) for transport to another recipient molecule. In the presence of oxygen, uric acid reacts with NO to produce the stable species 6-aminouracil. Uric acid uptake in adipocytes activates NADPH oxidase and increase production of ROS, which can initiate an inflammatory reaction. In vascular smooth muscle cells, uric acid can activate the NF-κB and MAPK pathway and increase cyclooxygenase and MCP-1 production. Blue arrows, chemical reactions; green arrows, products from enzymatic or signaling pathways; red arrows, activation of enzymatic activities.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
Referenced in 3 patents
On 2 Facebook pages
Mentioned in 2 Q&A threads
On 1 videos
Referenced in 1 clinical guideline sources
368 readers on Mendeley
1 readers on CiteULike
See more details